Emboline has raised $10.0M in total across 1 funding round.
Emboline's investors include Shangbay Capital.
Emboline, Inc. is a medical device company founded in 2011 and headquartered in Santa Cruz, California, specializing in embolic protection technology for cardiovascular interventions, particularly transcatheter aortic valve replacement (TAVR) procedures. Its flagship product, the Emboliner® Total-Body Embolic Protection System, is designed to capture and remove embolic debris released during heart procedures to reduce the risk of stroke, cognitive decline, kidney injury, and other ischemic complications. The device offers comprehensive protection by filtering debris from both cerebral and non-cerebral arterial beds, addressing a critical unmet need in interventional cardiology. Emboline serves interventional cardiologists and patients undergoing high-risk structural heart procedures, aiming to enhance procedural safety and outcomes. The company has demonstrated growth momentum through clinical milestones, including treating its first 100 patients in an investigational device exemption (IDE) study and expanding its intellectual property portfolio[1][4][5].
Emboline was founded in 2011 by Amir Belson, M.D., a physician and serial medical device entrepreneur with a strong background in cardiovascular innovation. Dr. Belson has a history of founding and scaling successful medical device companies, including NeoGuide Systems (acquired by Intuitive Surgical) and others focused on vascular and minimally invasive technologies. The idea for Emboline emerged from the need to address the stroke risk associated with TAVR and other interventional heart procedures, leveraging patented intellectual property invented by Dr. Belson. Early traction included partnerships for preclinical development and recognition of the urgent clinical demand for embolic protection in TAVR, culminating in the development of the Emboliner device and its clinical evaluation[1][2][3].
Emboline is positioned at the intersection of two major trends: the rapid growth of minimally invasive structural heart interventions like TAVR and the increasing clinical emphasis on reducing procedural complications such as stroke. As TAVR expands to lower-risk and younger patient populations, the demand for safer, more effective embolic protection technologies intensifies. Emboline’s total-body protection approach aligns with market forces pushing for comprehensive patient safety and improved long-term outcomes. The company’s innovations contribute to advancing interventional cardiology by enabling more confident adoption of complex procedures and potentially setting new standards for embolic protection in cardiovascular care[2][4][5].
Looking ahead, Emboline is likely to focus on expanding clinical validation, regulatory approvals, and commercial adoption of the Emboliner system. Trends shaping its journey include the broader adoption of TAVR and other catheter-based interventions, increasing awareness of embolic risks beyond the brain, and the push for integrated, easy-to-use protection devices. As the company scales, its influence may grow by setting new benchmarks in embolic protection technology and potentially expanding into other interventional fields with embolic risk. Emboline’s mission to eliminate TAVR-related stroke positions it as a critical player in improving cardiovascular procedural safety and patient outcomes in the coming years[1][3][5].
Emboline has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series B in April 2018.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2018 | $10.0M Series B | Shangbay Capital |
